Novo Nordisk ® tric growth hormone deficiency Key highlights Efficacy • Non-inferiority versus Norditropin ® for the primary endpoint, height velocity, at week 52 was confirmed • IGF-I SDS, bone age and glucose metabolism were all similar between Sogroya ® (somapacitan) and Norditropin ® Safety and tolerability • Overall the safety profile of somapacitan appeared to be similar to the well-known safety profile of daily GHD treatment • No local tolerability issues were identified Other treatment parameters • Significantly reduced treatment burden 1 compared to Norditropin ® Status • Adult GHD: Approved by the US, EU and JP • Paediatric GHD: Approved by the US, EU and JP y; IGF-I SDS: Insulin growth factor-1 standard deviation score; US: United States; EU: European Union; JP: Japan
Download PDF file